Literature DB >> 28133974

Novel therapeutic approaches in chondrosarcoma.

Genovefa Polychronidou1, Vasilios Karavasilis1, Seth M Pollack2, Paul H Huang3, Alex Lee4, Robin L Jones4,5.   

Abstract

Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally challenging. Current research focuses on elucidating the molecular events underlying the pathogenesis of this rare bone malignancy, with the goal of developing new molecularly targeted therapies. Signaling pathways suggested to have a role in chondrosarcoma include Hedgehog, Src, PI3k-Akt-mTOR and angiogenesis. Mutations in IDH1/2, present in more than 50% of primary conventional chondrosarcomas, make the development of IDH inhibitors a promising treatment option. The present review discusses the preclinical and early clinical data on novel targeted therapeutic approaches in chondrosarcoma.

Entities:  

Keywords:  HDACIs; Hedgehog pathway; IDH1/2; Src pathway; chondrosarcoma; novel agents; treatment

Mesh:

Substances:

Year:  2017        PMID: 28133974     DOI: 10.2217/fon-2016-0226

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  30 in total

Review 1.  CORR ® Tumor Board: Do Orthopaedic Oncologists Agree on the Diagnosis and Treatment of Cartilage Tumors of the Appendicular Skeleton?

Authors:  Megan E Anderson; Jim S Wu; Sara O Vargas
Journal:  Clin Orthop Relat Res       Date:  2017-06-06       Impact factor: 4.176

2.  Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells.

Authors:  William P Shield; Ashley Cellini; Hongying Tian; Kim Wilson; Yang Dan; Joshua M Abzug; Sonia Garcia; Norifumi Moritani; Ivan Alferiev; Michael Chorny; Masaharu Takigawa; Vincent Y Ng; Masahiro Iwamoto; Motomi Enomoto-Iwamoto
Journal:  J Orthop Res       Date:  2019-12-19       Impact factor: 3.494

Review 3.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

4.  Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors.

Authors:  Tahir N Sheikh; Xiao Chen; Xinjing Xu; John T McGuire; Matthew Ingham; Chao Lu; Gary K Schwartz
Journal:  Mol Cancer Ther       Date:  2021-09-22       Impact factor: 6.009

Review 5.  Targeted Therapies in the Treatment of Sarcomas.

Authors:  Brianna Hoffner; Anthony D Elias; Victor M Villalobos
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

6.  Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma.

Authors:  Megan E Roche; Zhao Lin; Diana Whitaker-Menezes; Tingting Zhan; Karoly Szuhai; Judith V M G Bovee; John A Abraham; Wei Jiang; Ubaldo Martinez-Outschoorn; Atrayee Basu-Mallick
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-10       Impact factor: 5.187

7.  Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.

Authors:  Makoto Nakagawa; Fumihiko Nakatani; Hironori Matsunaga; Takahiko Seki; Makoto Endo; Yoko Ogawara; Yukino Machida; Takuo Katsumoto; Kazutsune Yamagata; Ayuna Hattori; Shuhei Fujita; Yukiko Aikawa; Takamasa Ishikawa; Tomoyoshi Soga; Akira Kawai; Hirokazu Chuman; Nobuhiko Yokoyama; Suguru Fukushima; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Takeshi Hirose; Toshifumi Fujiwara; Nokitaka Setsu; Yoshihiro Matsumoto; Yukihide Iwamoto; Yasuharu Nakashima; Issay Kitabayashi
Journal:  Oncogene       Date:  2019-08-12       Impact factor: 9.867

8.  Dysregulation of Zinc Finger Protein 395 Contributes to the Pathogenesis of Chondrosarcoma.

Authors:  Changbao Chen; Hua Zhou; Zhongjun Liu; Xinlong Ma
Journal:  Onco Targets Ther       Date:  2021-06-01       Impact factor: 4.147

Review 9.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Constitutive GLI1 expression in chondrosarcoma is regulated by major vault protein via mTOR/S6K1 signaling cascade.

Authors:  Wei Wang; Taiqiang Yan; Wei Guo; Jianfang Niu; Zhiqing Zhao; Kunkun Sun; Hongliang Zhang; Yiyang Yu; Tingting Ren
Journal:  Cell Death Differ       Date:  2021-02-26       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.